» Articles » PMID: 24499110

Comparative Effectiveness of Two Metronomic Chemotherapy Schedules-our Experience in the Preclinical Field

Overview
Journal Cancer Invest
Specialty Oncology
Date 2014 Feb 7
PMID 24499110
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Metronomic chemotherapy refers to the chronic, equally spaced, delivery of low doses of chemotherapeutic drugs, without extended interruptions. Previously, we developed two combined metronomic schemes for the treatment of murine mammary tumors. The aim of this study was to compare their effects on tumor and metastasis growth, survival, and toxicity. Metronomic chemotherapy with Cyclophosphamide + Celecoxib (Cy + Cel) showed higher antimetastatic power than Cyclophosphamide + Doxorubicin (Cy + Dox), while being similar in other aspects. That difference, plus the advantage that represents its oral administration, suggests that the Cy + Cel combination is more suitable than Cy + Dox for metronomic chemotherapy of mammary tumors and could be proposed to the translation to the clinic.

Citing Articles

Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer.

Niu J, Wang Y, Wang J, Bin L, Hu X Aging (Albany NY). 2017; 8(12):3520-3534.

PMID: 28039440 PMC: 5270684. DOI: 10.18632/aging.101146.


Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, Argentina.

Rose A, Andre N, Rozados V, Mainetti L, Menacho Marquez M, Rico M Ecancermedicalscience. 2016; 10:672.

PMID: 27610198 PMC: 5014555. DOI: 10.3332/ecancer.2016.672.


Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.

Gao J, Wen S, Feng S, Yang W, Lu Y, Tong H Angiogenesis. 2016; 19(4):501-11.

PMID: 27380212 PMC: 5026725. DOI: 10.1007/s10456-016-9522-9.


Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.

Bouche G, Andre N, Banavali S, Berthold F, Berruti A, Bocci G Ecancermedicalscience. 2014; 8:463.

PMID: 25228919 PMC: 4162678. DOI: 10.3332/ecancer.2014.463.